| 1 |
Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutritioninflammation complex syndrome in dialysis patients: causes and consequences [J]. Am J Kidney Dis,2003,42(5):864-881.
|
| 2 |
Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease [J]. Kidney Int, 2008, 73(4):391-398.
|
| 3 |
Combe C, Chauveau P, Laville M. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients[J]. Am J Kidney Dis,2001,37(1 Suppl 2): S81-S88.
|
| 4 |
Lacson E Jr, Ikizler TA, Lazarus JM. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs [J]. J Ren Nutr,2007,17(6):363-371.
|
| 5 |
Cheung W,Yu PX,Little BM,et al. Role of leptin and melanoeortin signaling in uremia-associated cachexia[J]. J Clin Invest, 2005,115(6):1659-1665.
|
| 6 |
Yoshimoto A,Mori K, Sugawara A,et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease:a longitudinal study. Plasma ghmlin and dcsacyl gbIrelin concentration in renal failure [J]. J Am Soc Nephrol, 2002, 13(11):2748-2752.
|
| 7 |
Cohen S, Brault JJ, Gygi SP, et al. During muscle atrophy,thick,but not thin,filament components are degraded by MuRFI-dependent ubiquitylation [J].J Cell Biol,2009,185(6):1083-1095.
|
| 8 |
Wang XH,Du J,Klein JD,et al.Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function [J].Kidney Int,2009,76(7):751-759.
|
| 9 |
Lee SJ.Genetic analysis of the role of proteolysis in the activation of latent myostatin [J].PLoS One,2008,3(2): e1628.
|
| 10 |
Goraya N, Simoni J, Jo CH3, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate [J]. Kidney Int, 2014, [Epub ahead of print].
|
| 11 |
Rajah V, Mitch WE. Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease [J].Biochim Biophys Acta,2008,1782(12):795-799.
|
| 12 |
王玲,袁伟杰,谷立杰,等.糖皮质激素诱导胰岛素样生长因子l降低对原发性肾病综合征患者骨代谢的影响[J].中华肾脏病杂志,2011,27(2):82-86.
|
| 13 |
Sandri M,Sandri C,Gilbert A,et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-l and cause skeletal muscle atrophy [J].Cell,2004,117(3):399-412.
|
| 14 |
Zhang LP,Du J,Hu Z,et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting [J]. J Am Soc Nephrol,2009,20(3):604-612.
|
| 15 |
Caglar K, Fedje L, Dimmitt R, et al. Therapeutic effects of oral nutritional supplementation during hemodialysis [J]. Kidney Int,2002,62(3):1054-1059.
|
| 16 |
Cano NJ,Fouque D,Roth H,et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients:a 2-year multicenter, prospective, randomized study [J]. J Am Soc Nephrol,2007,18(9):2583-2591.
|
| 17 |
唐知还, 郝静, 袁伟杰,等. 运用主观评估法评价α 酮酸对老年透析患者营养的改善作用[J]. 中国血液净化杂志, 2008, 7(6):307-310.
|
| 18 |
Remels AH, Langen RC, Gosker HR, et al. PPAR gamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle[J]. Am J Physiol Endocrinol Metab,2009,297(1):E174-E183.
|
| 19 |
Narkar VA, Downes M, Yu RT, et al. AMPK and PPAR-delta agonists are exercise mimetics [J]. Cell, 2008, 134(3): 405-415.
|
| 20 |
Kopple JD, Wang H, Casaburi R, et al. Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle [J]. J Am Soc Nephrol, 2007, 18(11):2975-2986.
|
| 21 |
Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized,controlled trial[J]. J Am Soc Nephrol,2006,17(8):2307-2314.
|
| 22 |
Cheema B, Abas H, Smith B, et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD:The Progressive Exercise for Anabolism in Kidney Disease study[J]. Am J Kidney Dis,2007,50(4):574-584.
|
| 23 |
K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J]. Am J Kidney Dis,2005,45(4 Suppl 3): S1-S153.
|
| 24 |
余毅, 袁伟杰, 张国兆, 等. 血液透析患者代谢性酸中毒对机体营养状况的影响[J]. 福州总医院学报, 2005, 12(2): 108-110.
|
| 25 |
Stein A, Moorhouse J, Iles-Smith H, et al. Role of an improvement in acid-base status and nutrition in CAPD patients [J]. Kidney Int,1997,52(4):1089-1095.
|
| 26 |
Pickering WP, Price SR, Bircher G, et al. Serum bicarbonate and the ubiquitin-proteasome system in muscle [J]. Kidney Int, 2002,61(4):1286-1292.
|
| 27 |
De Brito-Ashurst I, Varagunam M, Raftery MJ, et al. Bicarbonate supplementation slows progression of CKD and improve nutritional status [J]. J Am Soc Nephrol,2009,20(9):2075-2084.
|
| 28 |
Adams J, Kauffman M. Development of the proteasome inhibitor Velcade [J]. Cancer Investigation,2004,22(2):304-311.
|
| 29 |
Siew ED, Ikizler TA. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease [J].Semin Dial,2010,23(4):378-382.
|
| 30 |
Pupim LB, Flakoll PJ, Yu C, et al. Recombinant human growth hormone improves muscle amino acid uptake and whole body protein metabolism in chronic hemodialysis patients [J]. Am J Clin Nutr,2005,82(6):1235-1243.
|
| 31 |
Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life and cardiovascular risk [J]. J Am Soc Nephrol,2007,18(7):2161-2171.
|
| 32 |
Deboer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease : improvements in lean body mass and cytokine profile [J]. Endocrinology,2008,149(2):827-835.
|
| 33 |
Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebocontrolled trial[J]. J Am Soc Nephrol,2005,16(7):2111-2118.
|
| 34 |
Leavey SF, Weitzel WF. Endocrine abnormalities in chronic renal failure [J]. Endocrinol Metab Clin North Am,2002,31(1):107-119.
|
| 35 |
Macdonald JH, Marcora SM, Jibani MM, et al. Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase Ⅱdose-finding study [J]. Nephron Clin Pract,2007,106(3): c125-c135.
|
| 36 |
Zhang L, Rajan V, Lin E, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease [J]. FASEB J, 2011, 25(5):1653-1663.
|
| 37 |
Almquist T, Jacobson SH, Mobarrez F, et al. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease [J]. Eur J Clin Invest,2014,44(3):276-284.
|